ClinicalTrials.gg
RecruitingNCT07502443Brilliance NT2Updated Oct 7, 2026

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2

A Phase 3 interventional study of ALKS 2680 Dose 1 and ALKS 2680 Dose 2 in Narcolepsy Type 2, sponsored by Alkermes, Inc.. Recruiting at 44 sites in 10 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Alkermes, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Updated Oct 7, 2026First site in Taiwan6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
176
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 248 studies in Sleep Wake Disorders with a site in United States — 34 open to participants now, 40 under way, 8 of them phase 3. Sleep Wake Disorders · United States.

Planned enrollment
54th of 203
176 · median 70
Started
2026
with 14 others
Phase 3
26 of 248
6 open now
Primary completion
2027-05
later than 12 of 39 live
Registered
241st of 248
by date
Lead sponsor
6 of 248
Alkermes, Inc.

Among the 248 studies in Sleep Wake Disorders with a site in United States, this one is the 54th largest by planned enrollment of the 203 interventional ones that give a count, is one of 15 that started in 2026, is one of 26 in phase 3, reaches primary completion later than 12 of the 39 other live ones, and was the 241st registered.

Sleep Wake Disorders

747 studies on the registry are indexed under Sleep Wake Disorders; 182 are open to participants now.

Browse Sleep Wake Disorders studies →

Open to participants now

34 of the 248 studies in Sleep Wake Disorders with a site in United States are open now. Recruiting first, the newest first:

28 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 110 Sleep Wake Disorders studies recruiting now, 36 (33%) set no upper age limit and 54 (49%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 248 studies in Sleep Wake Disorders with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to measure decreases in daytime sleepiness, and disease symptoms in participants with Narcolepsy Type 2 (NT2) when taking ALKS 2680 tablets compared with placebo tablets.

03

Conditions studied

  • Narcolepsy Type 2

Keywords

  • Narcolepsy Type 2
  • NT2
  • Sleep
  • Sleep disorder
  • orexin-2 receptor agonist
  • excessive daytime sleepiness
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is willing and able, in the opinion of the Investigator, to understand and comply with protocol requirements, including the following: lifestyle considerations and restrictions, adherence to guidance, adherence to actigraphy and diary requirements, if receiving treatment for OSA, adherence to primary OSA therapy over the 30 days prior to Visit 1, and throughout the study, including during overnight visits.
  • Meets the diagnostic criteria of NT2 according to ICSD-3-TR guidelines, confirmed by diagnostic evaluations (either PSG/MSLT).

Exclusion criteria

Exclusion Criteria:

  • Has another comorbid sleep disorder or condition that may influence the sleep-wake cycle.
  • Has a history or presence of other (treated or untreated) illness, disease, abnormality, or surgical procedure that, in the opinion of the Investigator, might compromise participant safety, interfere with any study assessment, or affect the participant's ability to complete the study.
  • Is currently enrolled in another interventional clinical trial or has received any drug or used any interventional investigational device within 30 days prior to Visit 1. Participants previously enrolled in Study ALKS 2680-202 are not eligible for enrollment.
  • Is currently pregnant, breastfeeding, or is planning to become pregnant during the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
176 participants (estimated)

Study arms

  • Experimental
    ALKS 2680 Dose 1

    Drug: ALKS 2680 Dose 1

  • Experimental
    ALKS 2680 Dose 2

    Drug: ALKS 2680 Dose 2

  • Experimental
    ALKS 2680 Dose 3

    Drug: ALKS 2680 Dose 3

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugALKS 2680 Dose 1

    Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks

    Also known as: Alixorexton

  • DrugALKS 2680 Dose 2

    Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks

    Also known as: Alixorexton

  • DrugALKS 2680 Dose 3

    Participants will receive ALKS 2680 tablets, daily, orally, for 12 weeks

    Also known as: Alixorexton

  • DrugPlacebo

    Participants will receive placebo tablets, daily, orally for 12 weeks

06

What researchers measure

Primary outcomes

  1. Change in mean sleep latency (MSL) on Maintenance of Wakefulness Test (MWT) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change in Epworth Sleepiness Scale (ESS) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

  2. Percentage of participants who achieve a status of "none" or "mild" on Patient Global Impression-Severity (PGI-S) scale (general disease) at Week 12 by dose level

    Time frame: Week 12

  3. Change in British Columbia Cognitive Complaints Inventory (BC-CCI) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

  4. Change in number of lapses on Psychomotor Vigilance Task (PVT) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

  5. Change in Patient-Reported Outcomes Measurement Information System - Fatigue 6a (PROMIS Fatigue 6a) from baseline to Week 12 by dose level

    Time frame: Baseline to Week 12

  6. Percentage of participants who achieve a status of "normal, not ill at all", "borderline ill", or "mildly ill" on Clinical Global Impression-Severity (CGI-S) (general disease) at Week 12 by dose level

    Time frame: Week 12

  7. Incidence of treatment emergent adverse events

    Time frame: Up to 14 weeks

07

Study locations

43 of 44 sites recruiting
  • Alkermes Investigational Site
    Cullman, Alabama 35055, United States
    Recruiting
  • Alkermes Investigational Site
    Phoenix, Arizona 85054, United States
    Recruiting
  • Alkermes Investigational Site
    Los Angeles, California 90025, United States
    Recruiting
  • Alkermes Investigational Site
    Boulder, Colorado 80301, United States
    Recruiting
  • Alkermes Investigational Site
    Brandon, Florida 33511, United States
    Recruiting
  • Alkermes Investigational Site
    Maimi, Florida 33176, United States
    Recruiting
  • Alkermes Investigational Site
    Winter Park, Florida 32789, United States
    Recruiting
  • Alkermes Investigational Site
    Macon, Georgia 31210, United States
    Recruiting
  • Alkermes Investigational Site
    Stockbridge, Georgia 30281, United States
    Recruiting
  • Alkermes Investigational Site
    Kansas City, Kansas 66160, United States
    Recruiting
  • Alkermes Investigational Site
    Newton, Massachusetts 02459, United States
    Recruiting
  • Alkermes Investigational Site
    Lansing, Michigan 48911, United States
    Not yet recruiting
  • Alkermes Investigational Site
    Novi, Michigan 48377, United States
    Recruiting
  • Alkermes Investigational Site
    Rochester, Minnesota 55905, United States
    Recruiting
  • Alkermes Investigational Site
    Charlotte, North Carolina 28210, United States
    Recruiting
  • Alkermes Investigational Site
    Huntersville, North Carolina 28078, United States
    Recruiting
  • Alkermes Investigational Site
    Cincinnati, Ohio 45245, United States
    Recruiting
  • Alkermes Investigational Site
    Wyomissing, Pennsylvania 19610, United States
    Recruiting
  • Alkermes Investigational Site
    Columbia, South Carolina 29201, United States
    Recruiting
  • Alkermes Investigational Site
    Austin, Texas 78731, United States
    Recruiting
  • Alkermes Investigational Site
    Frisco, Texas 75033, United States
    Recruiting
  • Alkermes Investigational Site
    San Antonio, Texas 78229, United States
    Recruiting
  • Alkermes Investigational Site
    Sugar Land, Texas 77478, United States
    Recruiting
  • Alkermes Investigational Site
    Sydney, New Sout 2113, Australia
    Recruiting
  • Alkermes Investigational Site
    Bruges, 8000, Belgium
    Recruiting
  • Alkermes Investigational Site
    Edegem, 2650, Belgium
    Recruiting
  • Alkermes Investigational Site
    Ghent, 9000, Belgium
    Recruiting
  • Alkermes Investigational Site
    Namur, Belgium
    Recruiting
  • Alkermes Investigational Site
    Markham, Ontario L3R 1A3, Canada
    Recruiting
  • Alkermes Investigational Site
    Toronto, Ontario M5S 3A3, Canada
    Recruiting
  • Alkermes Investigational Site
    Bordeaux, France
    Recruiting
  • Alkermes Investigational Site
    Lyon, France
    Recruiting
  • Alkermes Investigational Site
    Montpellier, France
    Recruiting
  • Alkermes Investigational Site
    Bologna, Italy
    Recruiting
  • Alkermes Investigational Site
    Kitakyushu-shi, Fukuoka 802-0084, Japan
    Recruiting
  • Alkermes Investigational Site
    Osaka, Osaka 532-0003, Japan
    Recruiting
  • Alkermes Investigational Site
    Shibuya-ku, Tokyo-To 151-0053, Japan
    Recruiting
  • Alkermes Investigational Site
    Shinjuku-ku, Tokyo-To 162-0851, Japan
    Recruiting
  • Alkermes Investigational Site
    Kumamoto, 862-0954, Japan
    Recruiting
  • Alkermes Investigational Site
    Tokyo, 152-8552, Japan
    Recruiting
  • Alkermes Investigational Site
    Heeze, Netherlands
    Recruiting
  • Alkermes Investigational Site
    Barcelona, Spain
    Recruiting
  • Alkermes Investigational Site
    Madrid, 28006, Spain
    Recruiting
  • Alkermes Investigational Site
    Kaohsiung City, 807, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for May 2027, 13 months after the start.

Of 19 phase 3 interventional studies under Sleep Wake Disorders, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 60. This study's planned 13 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2026
First posted
Mar 31, 2026
StartActual
Apr 22, 2026
Primary completionEst.
May 2027
CompletionEst.
Jun 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first site in Taiwan
Show 6 added (2 Japan, 1 United States, 1 Belgium, 1 Spain, 1 Taiwan)
  • Alkermes Investigational Site · Rochester, United States
  • Alkermes Investigational Site · Ghent, Belgium
  • Alkermes Investigational Site · Kumamoto, Japan
  • Alkermes Investigational Site · Tokyo, Japan
  • Alkermes Investigational Site · Madrid, Spain
  • Alkermes Investigational Site · Kaohsiung City, Taiwan
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    6 sites added — first site in Taiwan
    Show 6 added (2 Japan, 1 United States, 1 Belgium, 1 Spain, 1 Taiwan)
    • Alkermes Investigational Site · Rochester, United States
    • Alkermes Investigational Site · Ghent, Belgium
    • Alkermes Investigational Site · Kumamoto, Japan
    • Alkermes Investigational Site · Tokyo, Japan
    • Alkermes Investigational Site · Madrid, Spain
    • Alkermes Investigational Site · Kaohsiung City, Taiwan
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07502443
Lead sponsor
Alkermes, Inc.
Responsible party
Sponsor
First posted
Mar 31, 2026
Start date
Apr 22, 2026
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Director Clinical Trial Manager
Contact
clinicaltrials@alkermes.com
888-235-8008 (US Only)
Director Clinical Trial Manager
Contact
clinicaltrials@alkermes.com
571-599-2702 (Global)
Study Director, MD
study director · Alkermes, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion